<DOC>
	<DOCNO>NCT00978042</DOCNO>
	<brief_summary>Multicenter , single-blind , randomize , `` no-treatment '' control study demonstrate safety effectiveness VOLUMA XC deep injection cheek augmentation correct age-related volume deficit mid-face .</brief_summary>
	<brief_title>Safety Effectiveness Juvéderm® VOLUMA XC Injectable Gel Cheek Augmentation</brief_title>
	<detailed_description />
	<criteria>Male female , 3565 year age Zygomaticomalar region , anteromedial cheek , submalar region , and/or overall midfacial volume deficit assess Treating Investigator grade 3 , 4 , 5 photometric MidFace Volume Deficit Scale ( MFVDS ) Desire cheek augmentation correct agerelated volume deficit midface Accept obligation receive facial procedure treatment affect facial volume deficit time study Received ( plan receive ) anticoagulation , antiplatelet , thrombolytic medication ( e.g. , warfarin ) , antiinflammatory drug [ oral/injectable corticosteroid NonSteroidal AntiInflammatory Drugs ( NSAIDs ) ] , substance know increase coagulation time 10 day pre 3 day post injection [ Study device injection may delay necessary accommodate 10day washout period . ] Have undergone facial plastic surgery ( exception rhinoplasty 2 year prior enrollment ) , tissue grafting , tissue augmentation silicone , fat , permanent , semipermanent dermal filler plan undergo procedure time study Have undergo temporary facial dermal filler injection hyaluronic acidbased filler within 12 month , porcinebased collagen filler within 24 month , neuromodulator injection , mesotherapy , resurface within 6 month prior entry study planning undergo procedure time study Have begin use new overthecounter prescription , oral topical , antiwrinkle product treatment area within 90 day prior enrollment plan begin use product time study . Have thin skin midfacial region , tendency accumulate fluid lower eyelid , large infraorbital fat pad Have midface volume deficit due congenital defect , trauma , abnormality adipose tissue relate immunemediated disease generalize lipodystrophy , partial lipodystrophy , inherited disease , HIVrelated disease Have history anaphylaxis , multiple severe allergy , atopy , allergy lidocaine ( amidebased anesthetic ) , hyaluronic acid product , Streptococcal protein , plan undergo desensitization therapy term study Have noticeable acne scarring , active inflammation , infection , cancerous precancerous lesion , unhealed wound undergone radiation treatment area treat</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>